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AbstrAct:
Senescence is a valid tumor suppressive mechanism in cancer. Accelerated 
cell senescence describes the growth arrested state of cells that have been 
treated with anti-tumor drugs, such as doxorubicin that induce a DNA damage 
response. Discodermolide, a microtubule-stabilizing agent, is a potent inducer 
of accelerated cell senescence. Resistance to discodermolide is mediated via 
resistance to accelerated cell senescence, and is associated with reduced 
expression of the mTORC1 substrate, 4E-BP1 and increased expression of p53 [1]. 
Although the association of p53 with senescence induction is well-characterized, 
senescence reversion in the presence of high expression of p53 has not been 
well-documented. Furthermore, studies addressing the role of mTOR signaling 
in regulating senescence have been limited and recent data implicate a novel, 
senescence-associated role for 4E-BP1 in crosstalk with the transcription factor 
p53. This research perspective will address these somewhat contradictory findings 
and summarize recent research regarding senescence and mTORC1 signaling.
senescence
Cellular senescence was first described in a study 
examining the proliferative potential of diploid fibroblasts 
that had been isolated from human fetal tissue. In this 
study Hayflick and Moorehead described the restricted life 
span of cells in culture [2]. Later, Hayflick hypothesized 
that  the  limited  proliferative  capacity  of  primary  cells 
in  culture  could  be  the  result  of  aging  or  senescence 
[3].  The  phenomenon  was  later  coined  the  “Hayflick 
limit”, to describe cells that had reached their maximum 
proliferative  capacity  and  underwent  replicative 
senescence. It is now known that cellular senescence is 
a growth arrest program that can be triggered by many 
stresses  including  telomere  shortening  (replicative 
senescence), overexpression of oncogenes such as Ras 
(oncogene-induced  senescence),  or  drug-induced  DNA 
damage  (accelerated  senescence)  (Figure  1).  However, 
the cellular program governing this growth arrest program 
is considered to be similar, regardless of the senescence 
trigger. This program is reported to include activation of 
the DNA damage response and increased p53 stability, 
which leads to transcription of pro-senescent genes such 
as p21 (Figure 1). This increased stability is the result 
of  abrogation  of  the  MDM2-p53  interaction.  Murine 
double minute 2, or MDM2, is an E3 ubiquitin ligase 
and the major negative regulator of p53 [4]. In normal 
cells, MDM2 is a transcriptional target of p53 creating a 
negative feedback loop that maintains p53 at low levels, 
but during stress, p53 escapes interaction with MDM2 
and accumulates in the nucleus to initiate transcription of 
target genes capable of inducing senescence. 
senescence As A therApy for 
cAncer treAtment
“Accelerated  cell  senescence”,  “premature 
senescence”,  and  “senescence-like  growth  arrest”  are 
interchangeable terms that refer to the proliferative arrest 
observed in tumor cells when treated with an anticancer 
agent. It has long been appreciated that tumor cells have 
many different responses to chemotherapy and radiation, Oncotarget 2011; 2:  89 - 98 90 www.impactjournals.com/oncotarget
the best characterized of which is apoptosis that results 
in the clearance of affected tumor cells. This is equated 
clinically with either a partial or complete response to 
therapy, mediated by regression of tumor cells. However, 
many tumors are resistant to apoptosis and senescence 
induction is considered a viable option since senescent 
cells in vivo, are cleared by macrophages [5], thus tumor 
regressions may also be achieved. The caveat to this is 
the fact that in some situations, clearance of senescent 
cells does not occur, for example RAF-mutant senescent 
cells  that  comprise  benign  nevi.  Efforts  are  underway 
to understand the various cellular contexts under which 
senescent cells persist or become cleared by the immune 
system. 
Furthermore, drug-induced proliferative arrest and 
quiescence are clinically relevant responses that manifest 
as stable disease in cancer patients. Unlike senescence, 
quiescence is an easily reversible process and cancer cells 
can  resume  proliferation  when  treatment  ceases,  upon 
growth factor stimulation, or due to epigenetic mechanisms 
that mediate resistance to therapy [6, 7]. Senescence is 
considered a potent tumor suppressive mechanism in vivo 
and thus, is regarded as a negative regulator of oncogenic 
transformation [5, 8-12]. Thus, the induction of senescence 
as a treatment modality for cancer is considered a viable 
approach  for  the  clinical  management  of  malignancy, 
with the understanding that proliferative arrest may be 
the predominant mechanism. Senescence-inducing drugs 
may also be utilized in combination with other therapies 
to potentiate either apoptosis or growth arrest in tumor 
cells [13]. 
tubulin-stAbilizing Drugs As 
inDucers of senescence
DNA damaging agents such as doxorubicin, cisplatin, 
and ionizing radiation have been well characterized as 
inducers of accelerated cell senescence [14]. In addition 
to these agents, we and others have demonstrated that 
microtubule-stabilizing  agents  such  as  discodermolide, 
and to a much lesser extent Taxol, can induce accelerated 
cell senescence [15, 16] (Figure 2). 
Discodermolide,  which  was  isolated  from  the 
Caribbean  sea  sponge  discodermia dissoluta,  is  a 
microtubule-stabilizing  agent  that  was  originally 
characterized  as  an  immunosuppressant  [17-20]. 
Discodermolide  is  more  water  soluble  than  Taxol, 
interacts synergistically with Taxol to suppress the growth 
of numerous cancer cell lines [21, 22], does not exhibit 
cross-resistance to Taxol-resistant cells, and importantly as 
noted above, is a potent inducer of accelerated senescence 
[15]. Lastly, discodermolide resistant cells do not exhibit 
classical mechanisms of resistance observed in cells that 
have lost sensitivity to Taxol, rendering discodermolide 
and its analogs promising candidates for future clinical 
development.
Ixabepilone  is  an  analog  of  epothilone  B,  a 
microtubule  stabilizing  agent  originally  isolated  from 
the  gram-negative  bacteria,  Sorangium cellulosum.  It 
is FDA-approved for the treatment of metastatic breast 
cancer  in  taxane-refractory  patients.  At  present,  the 
senescent-inducing properties of epothilones are poorly 
characterized.
mArkers of senescence
Accelerated cell senescence shares many of the well-
characterized markers of replicative and oncogene-induced 
senescence [23, 24]. These include, a large flat cellular 
morphology;  expression  of  a  Senescence-Associated 
β-galactosidase activity (SA-β-gal) that distinguishes them 
from quiescent cells; formation of intracellular vacuoles; 
resistance  to  mitogenic  stimulation  and  formation  of 
punctuate, highly condensed facultative heterochromatin 
called  Senescence-Associated-Heterochromatic  Foci 
(SAHF) [25, 26]. Proteins that have increased expression 
during senescence that have been used as markers include 
figure 1: the p53 senescence pathway. Several triggers such 
as overexpression of oncogenes, telomere dysfunction or attrition, 
and  genotoxic  stress,  which  includes  discodermolide  treatment, 
promote the increased activity of p53. P53 activity and stability is 
negatively regulated by MDM2 (Murine double minute 2) under 
normal  conditions.  Under  stress  conditions,  the  DNA  damage 
response is activated and p53 rapidly accumulates to increase the 
transcription of target genes that will promote either apoptosis or 
senescence depending on the severity of the damage response.
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cyclin  D1,  γH2AX,  IL-8,  IL-6  and  IGFBPs,  however 
upregulation  of  these  is  not  universally  observed  [25, 
27]. Senescent cells are metabolically active and translate 
a plethora of secretory factors that has been termed the 
senescence  associated  secretory  phenotype,  or  SASP. 
The  SASP  is  comprised  of  interleukins,  inflammatory 
cytokines, proteases, and extracellular matrix components 
[28]. Therefore, senescent cells, unlike quiescent cells, 
have  comparable  levels  of  overall  protein  synthesis 
to cycling cells except that the repertoire of translated 
mRNAs is dramatically altered.
One  interesting  molecular  marker  of  senescence 
is  plasminogen  activator  inhibitor  1  (PAI-1),  a  direct 
transcriptional target of p53 [29]. PAI-1 is an inhibitor of 
urokinase type plasminogen activator (uPA), a secreted 
protease  involved  in  extracellular  matrix  remodelling. 
Previously thought to be only a marker of the senescent 
phenotype, PAI-1, has been reported to be required for 
p53-mediated replicative senescence induction in primary 
mouse diploid fibroblasts and human BJ cells [30]. While 
PAI-1  is  strongly  induced  in  discodermolide-induced 
accelerated  cell  senescence,  knockdown  of  PAI-1  in 
human tumor cells does not prevent senescence, but rather 
decelerates senescence induction, suggesting that in this 
context, PAI-1 acts as a modulator of senescence onset, an 
observation that is consistent with the redundant nature of 
senescence (Laura Klein, unpublished data). 
the ‘permAnence’ of senescence
Although  senescence  is  a  tumor  suppressive 
mechanism in normal cells, recent studies suggest that 
senescence  may  promote  transformation  via  creation 
of  a  proinflammatory  microenviroment  by  the  SASP 
that  promotes  extracellular  remodeling.  Therefore,  the 
tumor  suppressive  potential  of  senescence  induction 
as a therapeutic strategy is limited by the concern that 
senescent cells may not be effectively cleared [27, 28, 
31,  32].  Furthermore,  the  clinical  implementation  of 
senescent-inducing  therapies  also  relies  somewhat  on 
the perception that senescence is  irreversible, although 
studies, including our own, indicate that accelerated cell 
senescence and oncogene-induced senescence can indeed 
be evaded [1, 27, 33, 34]. Importantly, senescence escape, 
or reversion, is not to be confused with evasion, in which 
cells that were not initially senescent outgrow and form 
the majority population.
In  a  given  population  of  stably  senescent  cells, 
there is presumably, a strong selection for escape. In the 
case of drug-induced accelerated senescence, it has been 
our experience that escape is challenging in cell culture, 
since it took several years for us to isolate a senescence-
resistant line [1]. It is reasonable to assume that in vivo, 
senescent cells may be in a more permissive environment 
for escape, and this may contribute to tumor progression. 
This logic seems particularly valid if one considers the 
effects of senescence-associated SASP induction on the 
surrounding extracellular matrix, which is poorly modeled 
in cell culture systems. 
Finally,  senescent  cells  have  areas  of  highly 
condensed  facultative  heterochromatin  called 
Senescence-Associated  -Heterochromatic  Foci  (SAHF), 
which are specialized domains of transcriptionally silent, 
senescence-associated  heterochromatic  foci  [35]. These 
repress the expression of proliferation-promoting genes 
and several studies have implicated epigenetic alterations 
as important events in senescence reversion. One gene 
that has been implicated in senescence reversion is the 
figure 2: Discodermolide-induced accelerated cell senescence. Senescence-associated  β-galactosidase  activity  in A549  lung 
carcinoma cells treated with control (DMSO) or, an IC50 concentration of discodermolide for 6 days. 
Control  Discodermolide Oncotarget 2011; 2:  89 - 98 92 www.impactjournals.com/oncotarget
methylation enzyme S-adenosylhomocysteine hydrolase, 
SAHH. Inactivation of SAHH permits escape from p53 
and Rb-mediated replicative senescence [36]. Therefore, 
S-adenosylhomocysteine  hydrolase  downregulation 
contributes to tumorigenesis, reinforcing the significance 
of  epigenetic  processes  in  senescence  and  cellular 
transformation. 
senescence, cAncer evolution 
AnD DifferentiAtion
Cancer  development  is  a  multistep  process  and 
senescent  tumor  cells,  if  not  cleared  by  phagocytosis, 
are  under  strong  selective  pressure  to  revert  and  may 
gradually acquire alterations that enable them to re-enter 
the cell cycle. As discussed previously, pro-inflammatory 
signaling  originating  from  senescent  tumor  cells,  may 
also  promote  localized  transformation  in  neighboring 
cells that manifests as tumor progression in vivo. This 
may rationalize the observation that tumors that initially 
respond to chemotherapy treatment often become resistant 
to drugs. Clonal expansion of these cells is believed to 
contribute to the progression of drug-resistant tumors. The 
emergence of a drug-resistant population from a senescent 
precursor has been termed neosis [37, 38]. Future studies 
to  identify  factors  that  make  this  escape  possible  are 
crucial to understanding both proliferation cues in the cell 
and cancer progression. 
Furthermore,  it  is  well  known  that  cancer  cell 
lines and tumors are genetically heterogeneous and this 
observation also applies to the basal level of senescence 
in  a  given  cancer  cell  population.  Specifically,  in 
some  breast  cancer  cell  lines,  senescent  cells  have 
been  identified  by  SA-β-gal  positivity,  suggesting  that 
the  senescence  machinery  is  intact  in  some  tumors. 
Interestingly,  high  numbers  of  senescent  cells  exist  in 
Figure 3: A simplified schematic of the PI3K/Akt/mTORC1 pathway. Growth factors or hormones can stimulate phosphatidylinositol 
3-kinase (PI3K) signaling. Additionally, PTEN is commonly mutated in cancer, causing increased Akt activity and signaling through mTORC1. 
Activation of PI3K activates Akt, which can phosphorylate TSC2 leading to the inactivation of the TSC1/2 inhibitor complex. Released 
from inhibition, Rheb can then activate mTORC1. Activated mTORC1 phosphorylates its downstream substrates p70S6k and 4E-BP1. 
Phosphorylation of p70S6k results in phosphorylation of rpS6. mTORC1 phosphorylation of 4E-BP1 releases 4E-BP1 from eIF4E on the 5′ 
cap of mRNA, and enhances cap-dependent translation. 4E-BP1 inhibits translation of Gas2, which increases the stability of p53 by binding 
m-calpain and inhibiting its protease activity towards p53. Genotoxic stress activates p53, which induces the transcription and expression of 
SESNs (SESN1 and SESN2). SESN phosphorylates and forms a complex with AMPK and TSC2 that results in the phosphorylation of TSC2, 
eventually leading to activation of mTORC1 and its substrates 4E-BP1 and p70S6k. 
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estrogen receptor positive-expressing breast cancer cell 
lines that are models for treatment-responsive luminal A 
and B disease. Conversely, substantially fewer senescent 
cells are found in breast cancer cell lines that are basal-
like, which represent patients with disease that although 
chemo-responsive, is at high risk for relapse [39]. These 
data suggest that the basal level of senescence in a tumor 
reflects  (a)  the  capacity  for  proliferation,  and  (b)  the 
differentiation status, which for breast cancer, guides the 
choice of treatment, and also predicts outcome to therapy. 
the key plAyers: mtor, 4e-bp1, AnD 
p53
The PI3K/Akt/mTOR signaling pathway is important 
in  cancer  progression  and  regulates  metabolism,  cell 
survival and cell growth [40] (Figure 3). The mammalian 
target of rapamycin (mTOR) pathway exists as two protein 
complexes in the cell, mTOR complex 1 and 2 (mTORC1 
and mTORC2, respectively), reviewed in [41]. Although 
the function of these complexes is still an area of active 
research,  mTORC1,  which  contains  mTOR,  Raptor, 
mLST8 and PRAS40, regulates protein synthesis and cell 
proliferation.  Conversely,  mTORC2,  contains  mTOR, 
Sin1,  Rictor,  mLIST8  and  PROTOR,  and  primarily 
regulates  movement  of  the  actin  cytoskeleton  and  cell 
spreading.  Rapamycin  is  an  immunosuppressant  that 
inhibits mTORC1 via binding to FKBP12 and together 
this complex binds and inhibits mTORC1 Ser/Thr kinase 
activity.  Previously,  it  was  thought  that  mTORC2  was 
rapamycin insensitive; however, prolonged treatment with 
rapamycin decreases mTORC2 complex formation [42]. 
Studies  investigating  the  role  of  mTOR  in  senescence 
have been limited, and focused on its known regulation 
of proliferation. Rapamycin has been reported to suppress 
senescence in a variety of cell lines [43, 44] and also has 
anti-aging effects that can increase life span in mice [45]. 
Additionally,  fasting  or  caloric  restriction  is  known  to 
decrease mTORC1 activity and contribute to longevity. 
A  recent  study  by  Sengupta  et  al.  demonstrates  that 
mTORC1 activity decreases the production of ketones by 
the liver, which is associated with aging, and suggests that 
the effects of mTORC1 activity on aging can be attributed 
to mTORC1’s role as a nutrient sensor [46]. 
4E-BP1  (eIF4E  binding  protein  1)  is  a 
downstream  substrate  of  mTORC1  that  regulates  cap-
dependent  translation.  4E-BP1  undergoes  hierarchical 
phosphorylation  by  mTORC1  leading  to  its  activation, 
reviewed in [47]. Inhibition of mTORC1 by drugs such as 
rapamycin dephosphorylates 4E-BP1, thereby enhancing 
its  association  with  the  mRNA  5′  cap-binding  protein, 
eIF4E, and suppressing cap-dependent translation (Figure 
3). Conversely, 4E-BP1 may be hyperphosphorylated by 
activated mTOR, leading to its dissociation from eIF4E 
and enhanced translation of a specific subset of growth 
promoting mRNAs [48]. eIF4E acts oncogenically, and 
when  overexpressed  induces  senescence  independently 
of other stimuli in primary cells. It is overexpressed in 
various malignancies [49, 50], however, the mechanism 
by which eIF4E induces oncogenic transformation is not 
well understood. 
In our recent paper we describe a cell line, AD32 that 
is resistant to senescence [1]. This resistance is dependent 
upon  4E-BP1,  as  re-expression  of  4E-BP1  reverted 
resistance  to  the  senescence-inducer  discodermolide.  It 
has been previously demonstrated that p53 controls the 
dephosphorylation of 4E-BP1 and inhibition of translation 
through mTORC1-dependent effects [44, 51, 52]. Later, 
it was discovered that activation of p53 led to increased 
transcription  of  negative  regulators  of  mTORC1  such 
as  PTEN,  AMPKβ,  and  TSC2  [53,  54].  The  precise 
mechanism  for  the  p53-mediated  activation  of AMPK 
was  unknown  until  Budanov  et  al.  demonstrated  that 
p53 initiates the transcription of sestrins in response to 
genotoxic stress [55]. The sestrin family of cytoplasmic 
proteins consists of SESN1, SESN2, and SESN3, all of 
which  function  in  antioxidant  defense  by  regenerating 
peroxiredoxins. In particular, SESN1 and SESN2 are able 
to negatively regulate mTOR, a redox sensitive kinase. 
However this was independent of their redox activity. Since 
redox-impaired mutants were able to suppress mTORC1 
as  efficiently  as  wild  type  [55].  Importantly,  sestrins 
mediate  mTORC1  suppression  via  AMPK  activation, 
which in turn phosphorylates TSC2, a negative regulator 
of mTORC1. Furthermore, AMPK can phosphorylate p53 
at Ser15, a site that enhances p53 stability and activation 
[56,  57].  This  AMPK-mediated  p53  stabilization  may 
result in a positive feedback loop, further indicating the 
importance of p53 and mTORC1 signaling in response to 
genotoxic stress [58]. In addition, 4E-BP1 has been shown 
to control the translation of Gas2, a protein that regulates 
p53 stability and senescence [59].
AD32  cells,  which  have  escaped  senescence, 
express high levels of stable p53 protein relative to the 
senescence-sensitive precursor cell line, A549. In addition, 
we  demonstrated  that  with  increasing  discodermolide 
resistance, p53 protein expression increased, while 4E-
BP1 expression decreased [1]. While our findings support 
previous  studies  that  had  established  a  relationship 
between  4E-BP1  and  p53  [51,  52,  59-61],  the  finding 
that increased levels of stabilized p53 was not associated 
with senescence, but rather, escape from senescence, was 
paradoxical. 
This finding led us to ponder the current paradigm 
that places p53 as an essential component in accelerated 
cell senescence. Increased p53 activity is a hallmark of 
cell senescence, but does p53 drive senescence induction? 
Can senescence happen in the absence of p53? Or, is it 
possible that p53 suppresses senescence? Links between 
p53,  p21  and  cellular  senescence  have  been  well 
established. It is certainly true in some primary mouse 
embryonic fibroblasts (MEFs), that replicative senescence Oncotarget 2011; 2:  89 - 98 94 www.impactjournals.com/oncotarget
requires p53 and cells can be immortalized by loss of 
p53, p19ARF, or Rb proteins [11]. However, differences 
in basal senescence between cell lines do exist, just as 
differences in the propensity for senescent cells to exhibit 
a SASP phenotype exist. For example, human cells seem 
to be more dependent upon p21 for growth arrest, whereas 
p21 is not essential for senescence in mouse fibroblasts 
[62]. Additionally, there are two known tumor suppressor 
pathways that regulate the senescence response, the p53 
pathway  and  the  p53-independent  or  p16INK4a/RB 
pathway. Each of these pathways integrates a variety of 
stress  signals  that  determine  whether  a  cell  undergoes 
senescence or apoptosis. In many cancer cell lines, p53 
is  mutated  or  mislocalized  and  p16  is  epigenetically 
silenced;  yet  these  cells  are  still  able  to  execute  the 
senescence program [16].
Recent studies, including our own, demonstrate that 
senescence  can  occur  in  cells  that  have  compromised 
p53 [15, 43, 63-65]. A recent study by Demidenko et al. 
indicates that p53 may act as a suppressor of senescence 
in certain contexts [44]. This model provides a possible 
explanation for the reversion of accelerated cell senescence 
that leads to the generation of AD32 cells, despite high 
expression of p53 and p21. In this study [44], cells were 
engineered to conditionally overexpress p21 and it was 
found that overexpression of p53 drove quiescence, while 
p21  drove  senescence.  Cells  induced  to  overexpress 
ectopic p21 became senescent, but this could be converted 
to  quiescence  by  p53  overexpression,  indicating  that 
p53-driven  suppression  of  the  senescent  phenotype 
may  override  senescence  driven  by  p21.  Furthermore, 
rapamycin was able to suppress the senescent phenotype, 
and also nutlin3a, an MDM2 antagonist that stabilizes p53. 
Interestingly, AD32 cells are cross resistant to rapamycin 
but have wild-type 4E-BP1 function, capable of binding 
eIF4E [1]. We have discovered that 4E-BP1 expression 
modulates  senescence,  as  restoration  of  expression 
made these cells susceptible to discodermolide-induced 
accelerated cell senescence. Partial knockdown of p53 in 
AD32 cells had essentially no effect on discodermolide-
induced  senescence  or  cytotoxicity,  thereby  indicating 
that 4E-BP1, in this system, may play a more significant 
role in the accelerated cell senescence response than p53. 
future Directions
It  is  known  that  eIF4E  acts  oncogenically 
if  overexpressed,  resulting  in  tumor  growth  [49]. 
Presumably,  its  oncogenic  activity  lies  in  its  ability  to 
direct the translation of specific mRNAs that participate 
in advancing the malignant phenotype [66]. Identification 
of transcripts that are bound by eIF4E has been elusive, 
with most studies utilizing eIF4E overexpression screens 
[67,  68].  The  putative  mRNA  targets  that  have  been 
discovered  include  cMYC,  cdk2,  cyclinD1,  MMP9, 
Mcl-1,  Bcl-2,  survivin,  VEGF,  and  FGF2  [66,  69-71]. 
Many  of  the  mRNAs  identified  play  crucial  roles  in 
cell growth, metastasis, angiogenesis, and cell survival. 
Undoubtedly,  there  are  vastly  more  that  remain  to  be 
identified. The mRNAs regulated by eIF4E are considered 
“weak” mRNAs since they are generally poorly translated 
and associate with the monosome fraction in polysome 
gradients, likely due to their highly structured 5′ UTRs. 
“Weak”  mRNAs  include  proto-oncogenes  and  growth 
factors, whereas “strong” mRNAs, include housekeeping 
genes, reviewed in [50]. Thus far, the precise mechanism 
that eIF4E utilizes to target particular mRNAs is unknown. 
It  would  be  of  value  to  characterize  the  repertoire  of 
transcripts bound to eIF4E under different conditions and 
in different tissues. It has been demonstrated that eIF4E 
is phosphorylated by MNK1 and MNK2 kinases and may 
be regulated by other kinases, depending on nutrient, or 
growth signals [72, 73]. As the main inhibitor of eIF4E, 
and a direct substrate of mTORC1, future studies should 
focus on transcripts inhibited by 4E-BP1.
To this end, we performed transcriptome analysis 
on  4E-BP1  overexpressing  cell  lines  and  identified 
several changes in p53 response genes and those involved 
in  the  DNA  damage  response,  supporting  a  role  for 
discodermolide as a senescence-inducer that elicits a DNA 
damage  response.  Since  p53  is  a  pleiotropic  signaling 
molecule  that  participates  in  a  multitude  of  cellular 
processes,  it  is  plausible  that  the  elevated  expression 
observed in AD32 cells simply reflects a high basal level 
of DNA damage that the cells acquired while senescent, 
which can be tolerated by the revertant AD32 population. 
In this model, AD32 cells may have adjusted the internal 
p53 ‘rheostat’ to proliferate in the presence of high p53 
expression.
Others have used polysomal fractionation combined 
with  microarray  analysis  to  identify  those  transcripts 
that are more efficiently translated [68, 74]. While these 
approaches enrich for mRNAs that are associated with 
ribosomes, they do not directly identify transcripts bound 
to eIF4E and 4E-BP1, or associated proteins that may 
contribute to eIF4E’s specificity for particular mRNAs. 
For  instance,  CPEB  is  a  RNA-binding  protein  that 
recognizes and binds a specific sequence in the 3′ UTR of 
mRNA in Xenopus laevis. The Xenopus 4E-BP, maskin, 
interacts  with  CPEB  and  together  with  other  proteins 
regulates the translation of mRNA [75, 76]. A study in 
Saccharomyces cerevisiae  has  identified  PUF  proteins, 
mRNA  binding  proteins  that  interact  with  the  yeast 
4E-BPs, eap1 and caf20. PUF proteins in combination 
with 4E-BPs mediate translation of a specific subset of 
mRNAs  [74].  Recent  studies  employing  RNA-Binding 
Protein Immunoprecipitation-Microarray Profiling (RIp-
Chip or ribonomic profiling) were able to identify RNP 
complexes that specifically associated with mRNAs that 
shared  biological  function  or  activity  [77-80].  Future 
studies will be able to identify which mRNAs are inhibited 
by 4E-BP1 and possible cognate factors that facilitate this Oncotarget 2011; 2:  89 - 98 95 www.impactjournals.com/oncotarget
specificity, and changes in the population of transcripts 
bound during senescence.
We cannot rule out the possibility that 4E-BP1 is 
a  multifunctional  protein,  that  regulates  senescence  in 
an  mTORC1-independent  manner.  Overexpression  of 
a  4E-BP1  Thr37/46Ala  nonphosphorylatable  mutant 
in  AD32  cells  was  able  to  partially  revert  resistance 
to  discodermolide,  indicating  that  the  function  of  4E-
BP1 in senescence may be independent from mTORC1 
phosphorylation.  Although  rapamycin  universally 
dephosphorylates  the  mTORC1  substrate  S6K,  it  does 
not cause 4E-BP1 dephosphorylation in every cell type 
[81], nor does it result in dissociation of the mTORC2 
complex in every case. These observations have led to 
the hypothesis that clinical response to rapalogs occurs 
in  tumors  that  have  dephosphorylation  of  4E-BP1  and 
S6K, and mTORC2 dissociation, although this has yet 
to be substantiated. Several groups, including ours have 
suggested  regulation  of  4E-BP1  by  additional  kinases, 
reviewed in [82]. In fact, we have clearly demonstrated 
that  dual  suppression  of  the  RAS-PI3K  by  combined 
MEK and rapalog treatment is highly synergistic and that 
mechanistically this is mediated via potent suppression of 
cap-dependent translation and dephosphorylation of S6 
and 4E-BP1 [83]. 
A less well-characterized role of 4E-BP1 is its ability 
to regulate the subcellular localization of eIF4E, as ~30% 
of 4E-BP1 is localized to the nucleus [84]. Importantly, 
nuclear  localization  is  prevented  in  the  presence  of 
oncogenic  RAS,  although  this  mechanism  is  not  well 
understood. 4E-BPs do not have nuclear localization or 
export motifs, so it appears that the nucleocytoplasmic 
trafficking of the protein may be regulated by RAS. These 
studies provide further evidence of mTORC-independent 
functions of 4E-BP1.
Phosphorylation  of  Ser15  of  p53  abrogates  the 
p53-MDM2 interaction, and AD32 cells have increased 
phosphorylation of Ser15. However, both MDM2 and p53 
are regulated by various kinases. For example, MDM2 
undergoes phosphorylation by AKT, a cell survival factor, 
at Ser166. Phosphoryation of MDM2 results in increased 
E3  ligase  activity,  targeting  p53  for  degradation.  It  is 
unclear how during DNA damage, p53 is able to elude 
ubiquitination  by  MDM2  so  rapidly.  Our  cells  contain 
increased levels of both MDM2 and p53. It has recently 
been discovered that microRNA 605 (mir605) regulates 
the p53-MDM2 interaction. Mir605 is a transcriptional 
target of p53 and participates in a positive feedback loop 
by  degrading  MDM2  [85].  This  mechanism  provides 
another  example  of  the  complexity  of  the  senescence 
response.  Adding  to  the  complexity,  mir605  when 
overexpressed preferentially induces apoptosis rather than 
senescence [85]. It is plausible that there may be other 
miRNAs  capable  of  regulating  senescence.  With  each 
new  discovery  about  p53  regulation,  new  possibilities 
arise, suggesting that there is a delicate balance between 
tumor suppression and oncogenesis with multiple levels 
of regulation. 
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